In this episode of BioBiz Buzz, your host Mike Ward explores a critical, but often underappreciated, driver of vision loss in retinal diseases; the breakdown of the blood–retina barrier (BRB). While anti-VEGF therapies have transformed outcomes in diabetic macular oedema (DME) and wet age-related macular degeneration (AMD), many patients continue to experience incomplete responses, recurrence, and progressive vision loss; highlighting the limitations of therapies that primarily target downstream pathology. 

Joined by Neuvasq’s Chief Scientific Officer Dr Ralph Laufer and retinal clinician-scientist Dr Wai Wong, the conversation examines a fundamentally different approach; one grounded in developmental biology. Neuvasq is targeting Wnt–βcatenin signalling, the master regulatory pathway for vascular barrier formation, using engineered multispecific antibodies designed to selectively activate the Gpr124/Reck receptor complex on retinal endothelial cells. 

The discussion explores how restoring barrier integrity, rather than simply suppressing vascular leakage, could enable more durable disease control, reduce treatment burden, and offer meaningful benefit to patients who fail current therapies. Preclinical data demonstrating reduced neovascularisation, reversal of disease phenotypes, and enhanced vascular normalisation provide early evidence for a potentially transformative shift from symptom management to true disease modification. 

Looking ahead, the episode also examines next-generation strategies, including trispecific antibodies that combine Wnt pathway activation with VEGF inhibition, an approach that could simultaneously suppress pathology and actively repair vascular function.

Ultimately, this episode addresses a pivotal question at the intersection of ophthalmology and biotech innovation: can reactivating the biology of the barrier itself deliver more durable, transformative outcomes than treating its downstream consequences?

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer  

● LinkedIn